A letter was sent to healthcare professionals about mirabegron for symptomatic treatment of urgency, increased
micturition frequency, or urgency incontinence.
In September 2015, a letter was sent to relevant healthcare professionals for mirabegron to inform of a risk of severe hypertension and associated cerebrovascular and cardiac events. Further information is provided in a Drug Safety Update article.
Article citation: Drug Safety Update vol 9 issue 3 October 2015: 2.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.